Fri­day IPO dou­ble­head­er from Maze and Met­sera brings life to biotech de­buts

Obe­si­ty drug de­vel­op­er Met­sera and kid­ney dis­ease biotech Maze Ther­a­peu­tics priced their Nas­daq IPOs on Thurs­day evening.

Met­sera $MT­SR will raise $275 mil­lion and Maze …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.